Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options - PubMed (original) (raw)

Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options

Karine Dubé et al. AIDS Res Hum Retroviruses. 2020 Dec.

Abstract

A growing body of research is beginning to elucidate reasons people living with HIV (PLWHIV) might prefer oral daily antiretroviral treatment (ART) compared with emerging long-acting ART (LA-ART) or HIV remission strategies under investigation. Our objective is to provide qualitative insights into the reasons why PLWHIV might prefer one of these HIV control therapies over others. From May to August 2018, we implemented a semistructured cross-sectional survey of PLWHIV in the United States to better understand patient preferences around various HIV treatment and remission options. Using free text, respondents were asked to explain why they preferred one HIV control option over the other two. We analyzed responses to the open-ended survey questions on reasons for preferring oral daily ART versus LA-ART versus HIV remission strategies using conventional content analysis. The results showed that PLWHIV preferred oral daily ART because of its familiarity and known safety and efficacy profile, whereas those who preferred LA-ART would value the convenience it offers. Finally, HIV remission strategies would be preferred to avoid taking ART altogether. The qualitative results provide insights into reasons why PLWHIV in the United States might prefer oral daily ART versus novel therapies. More importantly, they provide information to better align HIV virological control strategies with end-user perspectives. To make informed choices around evolving HIV therapeutics, PLWHIV and HIV care providers would benefit from decision tools to better assess options and trade-offs. More research is needed on how best to effectively support PLWHIV and HIV care providers in shared decision-making.

Keywords: HIV control; HIV cure research; HIV remission; antiretroviral treatment (ART); long-acting ART; people living with HIV.

PubMed Disclaimer

Conflict of interest statement

K.D., D.M.C., K.E.P., J.T.K., P.S., and J.A.S. have no conflict of interest to declare. D.E. participates in unpaid activities that are not part of this study for Gilead Sciences, Inc. T.P. has received research funding from Gilead Sciences, Inc.

Figures

FIG. 1.

Analytic coding tree—PLWHIV's preferences for oral daily ART versus LA-ART formulations versus HIV remission (United States, 2018). ART, antiretroviral treatment; LA-ART, long-acting antiretroviral treatment; PLWHIV, people living with HIV.

References

1. U.S. DHHS: FDA-Approved HIV Medicines. AIDSinfo (2020). Available at https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-ap..., accessed April28, 2020
1. Marcus JL, Chao CR, Leyden WA, et al. : Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. JAIDS 2016;73:39–46 -PMC -PubMed
1. Nachega J, Patienti J, Uthman O: Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis 2014;58:1297–1307 -PMC -PubMed
1. Buell KG, Chung C, Chaudhry Z, Puri A, Nawab K, Ravindran RP: Lifelong antiretroviral therapy or HIV cure: The benefits for the individual patient. AIDS Care 2016;28:242–246 -PubMed
1. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. : Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 2017;390:1499–1510 -PubMed

Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options - PubMed (original) (raw)